Sunitinib in Sarcomas of the Central Nervous System

NCT03641326 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

NIH

Sponsor class

Stopped Poor accrual

Conditions

Gliosarcoma
Central Nervous System Sarcoma

Interventions

DRUG: Sunitinib
DEVICE: wGT3x-BT

Sponsor

National Cancer Institute (NCI)